

## The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis

### Dong-Yang Wang, Yi Chen, You Zhang and Ying-Qiang Shen\*

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Medicine of Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, China

### **OPEN ACCESS**

### Edited by:

Rudolph M. Navari, World Health Organization (WHO), Guinea

irontiers

in Oncology

### Reviewed by:

Gamal Eldein Fathy Abd-Ellatef Abd-Elrahman, National Research Centre, Egypt Yaswanth Kuthati, Cathay General Hospital, Taiwan

> \*Correspondence: Ying-Qiang Shen shen@scu.edu.cn

### Specialty section:

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology

> Received: 07 May 2021 Accepted: 07 September 2021 Published: 30 September 2021

### Citation:

Wang D-Y, Chen Y, Zhang Y and Shen Y-Q (2021) The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. Front. Oncol. 11:705866. doi: 10.3389/fonc.2021.705866 **Introduction:** The aim of this study is to rigorously review the efficacy and safety of olanzapine in chemotherapy-induced nausea and vomiting (CINV) settings including (1) at 5- and 10-mg doses, and (2) the setting of highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).

**Methods:** Embase, Pubmed, and Cochrane Library were searched from the establishment of the database through April 18, 2021. The primary efficacy endpoints were the rate of complete response (CR; no emesis and no rescue), in the acute (0–24 h post-chemotherapy), delayed (24–120 h post-chemotherapy), and overall (0–120 h post-chemotherapy) phases. The secondary efficacy endpoints were the rates of complete control (CC, no nausea, and no emesis), for each phase. Safety endpoints were the rate of somnolence, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) criteria. The Mantel–Haenszel, random, or fixed-effect analysis model was used to compute risk ratios and accompanying 95% confidence intervals for each endpoint. For endpoints that statistically favored one arm, absolute risk differences were computed to assess whether there is a 10% or greater difference, used as the threshold for clinical significance by MASCC/ESMO.

**Result:** Nine studies reported the use of 10 mg olanzapine to prevent CINV; three studies reported the use of 5 mg olanzapine to prevent CINV. When olanzapine was administered at 10 mg for HEC patients, the six endpoints were statistically and clinically better than the control group. For MEC patients, four out of six endpoints were better than the control group. When olanzapine is administered at 5 mg for MEC patients, four endpoints have statistical and clinical advantages. The sedative effects of 10 and 5 mg olanzapine were statistically more significant than those of the control group. The sedative effect of the

1

10-mg olanzapine group was more significant than that of the 5-mg olanzapine group, both statistically and clinically.

**Conclusion:** 5 mg olanzapine may be as effective as 10 mg olanzapine for patients with HEC and MEC, and its sedative effect is lower than 10 mg olanzapine. Fewer studies on 5 mg olanzapine have led to uncertain data. In the future, more randomized controlled trials of 5 mg olanzapine are needed to study the balance between the effectiveness and safety of olanzapine.

Keywords: olanzapine, vomiting, nausea, meta-analysis, systematic review, antiemetics

### **1 INTRODUCTION**

Chemotherapy-induced nausea and vomiting (CINV) is a common treatment-related side effect that occurs at a rate of approximately 70%–80%. It adversely affects the quality of life of cancer patients and may lead to reduced or stopped chemotherapy (1, 2). Therefore, the prevention and control of CINV is a major clinical problem at present, and it is of clinical significance to study the effectiveness and safety of anti-spitting drugs. CINV can be divided into three phases: acute (the first 24 h after the start of chemotherapy) (3), delay (24 to 120 h after chemotherapy) 4, or overall phase (4)(0 to 120 h after chemotherapy).

The guidelines drawn up by the International Association establish a four-level classification of chemotherapy drugs, consisting of four categories: highly emetogenic chemotherapy (HEC), moderate emetogenic chemotherapy (MEC), low emetogenic chemotherapy, and minimum emetogenic chemotherapy (5). These four categories are based on the percentage of patients with acute vomiting caused by a single drug without anti-spitting prevention. However, the classification does not address the vomiting potential of the combined drug regimen, which is usually determined by the most spitting drug in the combined drug<sup>1</sup>.

The anti-spitting regimen has long been based on a two-drug regimen (including 5-serotonin-3 (5-HT3) receptor antagonists and multi-day dexamethasone) for the prevention of acute and delayed CINV (6). Neuropeptide (NK) 1-receptor antagonists (e.g., aprepitant, rolapitant, and netupitant) are considered promising antiemetics to CINV. Studies reported (7) that the addition of NK-1 receptor antagonists can significantly decrease CINV caused by HEC drugs.

Olanzapine (Olz) is an antipsychotic drug that acts on a variety of receptors. PIRL (8) first reported a case of olanzapine against CINV in 2000. A leukemia patient was in poor mental health due to severe CINV. However, his nausea and vomiting improved significantly after taking 5 mg of olanzapine every night. It is possible to bind to a variety of receptors in the CINV pathway, in particular serotonin receptors (5-HT2A, 5-HT2C, 5-HT3, 5-HT6) and dopamine receptors (D1, D2, D3, and D4) (9) to be non-label antiemetics.

In order to further verify the effect of olanzapine on CINV, Navari et al. (10, 11) conducted two phase II clinical trials in 2005 and 2007. Patients receiving HEC and MEC were given 5-HT3 antagonist and dexamethasone combined with olanzapine to evaluate the antiemetic effect. Another phase II clinical trial (12) showed that olanzapine was more effective in controlling CINV in patients with gynecological tumors in combination with a triple agent. Many Phase II and Phase III trials <sup>9-11</sup>were conducted on the effectiveness and safety of Olz recently.

A number of systematic reviews and meta-analyses were carried out. However, there is no meta-analysis of the balance between the effectiveness and safety of different doses of olanzapine. This important difference leads to different clinical guidelines recommended.

The Chinese Society of Clinical Oncology (CSCO) recommends olanzapine 5–10 mg and triple solutions to form a vomiting solution for HEC patients, compared to olanzapine and two-joint solution for MEC patients. The National Integrated Cancer Network (NCCN) recommends olanzapine 10 mg and triple regimen as an option for HEC patients (13). American Society of Clinical Oncology (ASCO) guidelines consider olanzapine 5 mg and triple regimen to be safe and effective for HEC patients (14). According to a recent Phase II clinical study (15), 5 mg olanzapine had a better antiemetic effect than 10 mg olanzapine, and its adverse reactions (e.g., sedation) were lower than those of the 10-mg olanzapine group. Therefore, it is necessary to conduct a meta-analysis of the effectiveness and safety of different doses of olanzapine.

In view of the growing interest in olanzapine, a more rigorous review is required. The purpose of this study is to examine the efficacy and safety of Olz in preventing and saving CINV through systematic review and meta-analysis. In addition, in view of the large amount of available data, the purpose of this review is to identify deficiencies in the available literature, providing direction for future research in the CINV environment.

### 2 METHOD

### 2.1 Inclusion and Exclusion Criteria

The inclusion criteria are as follows: type of study: published randomized controlled trial of olanzapine at different doses in combination with other agents to prevent CINV; subjects: adult cancer patients receiving HEC or MEC chemotherapy; control measures: a general regimen against chemotherapy-induced nausea and vomiting; intervention: olanzapine was added to the standard regimen; evaluation indicators: success rate of prevention of nausea and vomiting, incidence of sedation. The exclusion criteria are as follows: 1) repeated published literatures (literatures with the most complete and up-to-date data retained); 2) reviews, case reports, meeting abstracts, or trial registration literature; 3) it is not a study on antiemetic chemotherapy in adults or without olanzapine as a variable; 4) full text or incomplete data cannot be obtained.

### 2.2 Literature Retrieval Strategy

A computer search of PubMed, Embase, and Cochrane Library was conducted to collect published randomized controlled trials of olanzapine combined with other drugs at different doses for the prevention of CINV. The relevant literatures were searched from the establishment of the database to April 2021. In order to search the whole literature, we carry out the retrieval mode of subject words + free words, including drug therapy, vomiting or nausea, dexamethasone, olanzapine, and all kinds of free words. See **Appendix 1** for the specific retrieval method.

### 2.3 Literature Screening and Data Extraction

Literature screening, data extraction, and cross-checking were conducted by two researchers independently. In case of disagreement, consensus was reached through discussion or consultation with a third party. Literature screening was conducted by reading the title and abstract and further reading of the full text after excluding the apparently irrelevant literature to determine whether it was included or not.

Data extraction of the main content includes (1) the research of the basic characteristics, including research types, article name, year, authors, published by use of chemotherapy regimens, patients with cancer types, age, gender, patients' basic information, project for the time range, control group- and experimental group-specific regimen to prevent nausea and vomiting; (2) key elements of bias risk assessment; and (3) outcome indicators and outcome measurement data of concern. The primary efficacy endpoints were the rate of complete responses (CR) in the acute (0–24 h post-chemotherapy), delayed chemotherapy (24–120 h), and overall (0–120 h post-chemotherapy) phases. The secondary efficacy endpoints were the rates of complete control (no nausea and no nausea emesis, CC) for each phase and CR and CC in different chemotherapy regimens. The safety endpoint was the incidence of sedation.

### 2.4 Quality Evaluation of Included Studies

The Cochrane Risk Bias Assessment Tool was used independently by two investigators to assess the risk of bias in the included studies. The method includes 1) random sequence generation (selection bias); 2) allocation concealment (selection bias); 3) blinding of participants and personnel (performance bias); 4) blinding of outcome assessment (detection bias); 5) incomplete outcome data (attrition bias); 6) selective reporting (reporting bias); and 7) other bias. Each item is graded according to "high risk," "unclear," and "low risk."

### 2.5 Statistical Analysis

Meta-analysis of the included studies was performed using RevMan 5.4 software. Relative risk (RR) was used to combine the overall effect for categorical variables. Heterogeneity tests were carried out for the effect sizes of each combined study. If  $\rm I^2$  > was 50%, indicating heterogeneity, a random-effect model was used, otherwise a fixed-effect model was used. In the overall results, p < 0.05 was considered statistically significant. For endpoints that statistically favored one arm, absolute risk differences were computed to assess whether there is a 10% or greater difference, used as the threshold for clinical significance by MASCC/ESMO.

### **3 RESULTS**

### **3.1 Included Studies**

From the retrieval policy, 574 records were identified. After deleting 168 duplicate records, a total of 406 records entered the initial screening. Twenty-four studies were obtained by filtering titles and abstract. A second screening of the full text resulted in 12 studies. Twelve studies are reasonably excluded—five studies (16–20) only have Conference abstract, five studies (21–25) do not have specific experimental results, and two studies (26, 27) are unclear in method. A total of 12 studies (28–41) have eligibility criteria for systematic evaluation. All of these studies have been published in peer-reviewed journals. The PRISMA study selection diagram is shown in **Appendix 2**. **Table 1** provides an overview and characteristics of each study, as well as patient characteristics.

Eleven studies (28–34, 36–39) are randomized controlled experiments; one study (35)is a prospective control study; and nine studies (28–31, 33, 34, 37–39) compared 5 or 10 mg olanzapine with placebo, while three studies (32, 35, 36) compared the four-drug regimen with standard regimen; and 12 studies differed in the drugs used in the concurrent antiemetic regimens: a corticosteroid, 5-HT3 receptor antagonist, and NK1 receptor antagonist in seven studies (28–32, 36, 39) and a corticosteroid and 5-HT3 receptor antagonist in five studies (33–35, 37, 38).

All studies are CINV for adults. Nine studies (31–39) reported the use of 10 mg olanzapine to prevent CINV; three studies (28– 30, 40, 41) reported the use of 5 mg olanzapine to prevent CINV; five studies (31, 32, 37–41) included HEC patients; two studies (29, 33) included MEC patients; and five studies (28, 30, 34–36) included HEC and MEC patients. Of the five studies involving both HEC and MEC, only three studies (34–36) reported the results of HEC and MEC separately, and two studies were not enough for subgroup analysis; eight studies (28, 29, 31–35, 37) reported adverse reactions including sedation, **Table 2** provides the procedures of each study to evaluate the sedative effect of olanzapine; 11 studies (28–34, 36–39) are randomized controlled experiments; 1 study (35) is a prospective control study (40, 41); 9 studies used a double-blind placebo-controlled approach; and 3 studies (32, 35, 36) were unclear on blind methods.

All 12 studies reported a CR to antiemetic therapy and defined CR as no vomiting and no rescue; eleven studies (28–30, 32–39) reported a CC to antiemetic therapy and defined CC as no nausea and no emesis. No studies evaluated the bioavailability of the olanzapine in their articles. Only two studies (34, 39) mentioned the plasma half-life of olanzapine in the discussion.

### TABLE 1 | Study demographic.

| Reference                  | Country  | Design | Chemotherapy<br>emetogenicity | No. of<br>subjects | Age (mean) |          | Male, n (%) |            | Intervention's additional                     |  |
|----------------------------|----------|--------|-------------------------------|--------------------|------------|----------|-------------|------------|---|--|
|                            |          |        |                               |                    | Olanzapine | Placebo  | Olanzapine  | Placebo    | drug regimens, relative to<br>comparative arm |  |
| Clemons et al. (28)        | Canada   | RCT    | HEC/MEC                       | 218                | 50         | 52       | NR          | NR         | Olanzapine (5 mg oral/day)                    |  |
| Hashimoto et al. (16)      | Japan    | RCT    | MEC                           | 705                | 65         | 66       | 237 (67)    | 234 (67)   | Olanzapine (5 mg oral/day)                    |  |
| Mizukami et al. (30)       | Japan    | RCT    | HEC/MEC                       | 44                 | 63         | 55       | 11 (50)     | 11 (50)    | Olanzapine (5 mg oral/day)                    |  |
| Clemmons et al. (39)       | Canada   | RCT    | HEC                           | 101                | 54         | 56       | 29 (57)     | 31 (62)    | Olanzapine (10 mg oral/day                    |  |
| Vimolchalao et al. (38)    | Thailand | RCT    | HEC                           | 60                 | 55         | 53       | 10 (31.25)  | 10 (31.25) | Olanzapine (10 mg oral/day                    |  |
| Jeon et al. (33)           | Korea    | RCT    | MEC                           | 54                 | 60         | 63       | 23 (79)     | 22 (88)    | Olanzapine (10 mg oral/day)                   |  |
| Tienchaiananda et al. (37) | Thailand | RCT    | HEC                           | 39                 | 49.4       | 47.3     | 0           | 0          | Olanzapine (10 mg oral/day)                   |  |
| Mukhopadhyay et al. (34)   | India    | RCT    | HEC/MEC                       | 100                | 55.04      | 53.66    | 27 (54)     | 31 (62)    | Olanzapine (10 mg oral/day)                   |  |
| Navari et al. (31)         | America  | RCT    | HEC                           | 380                | 56         | 58       | 53 (27.6)   | 52 (27.7)  | Olanzapine (10 mg oral/day)                   |  |
| Tan et al. (36)            | China    | RCT    | HEC/MEC                       | 229                | M: 54.5    | M: 54    | 72 (59.5)   | 65 (60.2)  | Olanzapine (10 mg oral/day)                   |  |
|                            |          |        |                               |                    | F: 49.58   | F: 48.25 |             |            |   |  |
| Yeo et al. (32)            | China    | RCT    | HEC                           | 120                | 55.5       | 54.5     | 0           | 0          | Olanzapine (10 mg oral/day)                   |  |
| Osman et al. (35)          | Sudan    | PCS    | HEC/MEC                       | 131                | 46         | 50       | 14(28)      | 18(22.2)   | Olanzapine (10 mg oral/day)                   |  |

RCT, randomized controlled trial; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; NR, not reported; PO, per os; PCS, prospective comparative study; M, male; F, female.

TABLE 2 | The procedures to evaluate the sedative effect of olanzapine.

| Reference                                     | Assessment procedure  |
|---|---|
| Jeon et al. (33)                              | Adverse events were graded according to the terminology and grading categories defined in the NCI-CTCAE, ver. 4.03.   |
| Mukhopadhyay et al. (34)                      | Adverse events were reported by the patients on day 1, on day 3, and on day 8 and also at any time during the study period.   |
| Navari et al. (31)                            | A study nurse contacted each patient daily on days 2 through 5 to ask about toxic effects. Adverse events were graded according to the terminology and grading categories defined in the NCI-CTCAE, version 4.0.  |
| Osman et al. (35)                             | Patients were followed up by telephone interview daily from days 1 through 5. The interviewer assessed the severity of sedation, ranging from mild to moderate to severe, reflecting grade 1, grade 2, and grade 3 on CTCAE.  |
| Tienchaiananda et al. (37)                    | Details of adverse events were collected from all the daily record forms from 4 cycles of AC regimen.   |
| Yeo et al. (32)                               | Adverse events were graded according to NCI CTCAE v 4.0.  |
| Clemons et al. (28)<br>Hashimoto et al., 2019 | The NCI-CTCAE Version 4.02 was used to evaluate the side effects during the Day 2 and 6 telephone calls and at the post chemotherapy clinic visit.<br>Adverse events were assessed every 24 h during patients' hospital admission by clinical study personnel or attending physicians, according<br>to the NCI-CTCAE version 4.0. |

NCI-CTCAE, National Cancer Institute's Common Terminology Criteria for Adverse Events; CTCAE, Common Terminology Criteria for Adverse Events.

### 3.2 Quality of Included Studies

Each bias risk assessment included in the study is reported in the electronic **Supplementary Material** in **Appendix 3**. Since most studies are double-blind control experiments, the risk of bias in inclusion in the study is low.

## 3.3 Assessment for Publication Bias of Olanzapine for the Prophylaxis of CINV

The funnel diagram is shown in **Appendix 4** electronic **Supplementary Material**.

There is no obvious asymmetry, indicating that there is no obvious publishing bias in this literature.

# **3.4 Efficacy of Olanzapine for the Prophylaxis of CINV**

## 3.4.1 10 mg Olanzapine

### 3.4.1.1 Complete Response

For CR after chemotherapy, 10 mg olanzapine is statistically and clinically superior to the control protocol. For HEC patients, 10 mg Olz has advantages in acute (RR = 1.29, 95% CI = 1.07,1.56), delayed (RR = 1.64, 95% CI = 1.31,2.06), and overall (RR = 1.96, 95% CI = 1.54,2.49) CR (**Figure 1A**). For MEC patients, 10 mg of

Olz has advantages in delay (RR = 1.34, 95% CI = 1.15,1.56) and overall (RR = 1.33, 95% CI = 1.14,1.56) CR (**Figure 1B**).

Similarly, for acute (RD = 0.18), delayed (RD = 0.29), and overall (RD = 0.34) CR in HEC patients, as well as delay (RD = 0.21) and overall (RD = 0.20) CR in MEC patients, 10 mg of Olz has a clinical advantage (risk difference greater than 10%, **Table 3**).

### 3.4.1.2 Complete Control

For HEC patients, 10 mg Olz has statistical advantages in acute (RR = 1.40, 95% CI = 1.07,1.82), delayed (RR = 1.92, 95% CI = 1.20,3.08), and overall (RR = 2.24, 95% CI = 1.31,3.81) CC (**Figure 2A**). For MEC patients, 10 mg of Olz has statistical advantages in delayed (RR = 1.35, 95% CI = 1.09,1.67) and overall (RR = 1.37, 95% CI = 1.09,1.70) CC (**Figure 2B**).

Similarly, 10 mg of Olz was superior to the placebo control group clinically only for HEC patients in acute (RD = 0.16), delayed (RD = 0.19), and overall (RD = 0.22) CC (**Table 3**).

## 3.4.2 5 mg Olanzapine

### 3.4.2.1 Complete Response

For MEC patients, 5 mg olanzapine has statistical advantages in acute (RR = 1.07, 95% CI = 1.02, 1.12), delayed (RR = 1.20, 95% CI = 1.10, 1.32), and overall (RR = 1.23, 95% CI = 1.11, 1.35) CR (**Figures 1C, D**).

| Study or Subgroup         Events         Total         Events         Total         Weight           1.1.1 Acute CR         Clemmons et al 2018         39         51         31         50         13.0%  | Risk Ratio<br>M-H, Random, 95% Cl<br>1.23 (0.95, 1.61)      | Risk Ratio<br>M-H, Random, 95% Cl                       |  |
|--|---|---|--|
| Mukhopadhyay et al 2016 35 36 34 36 16.8%<br>Navari et al 2016 156 182 114 181 16.3%   | 1.03 [0.93, 1.13]<br>1.36 [1.20, 1.54]<br>1.33 [1.02, 1.75] | •<br>•  |  |
| Tan et al 2009         51         56         42         46         16.4%           Tienchaiananda et al 2019         15         20         7         19         5.7%           Vimolchalao et al 2020         24         32         10         32         6.9%     | 1.00 [0.88, 1.13]<br>2.04 [1.07, 3.86]<br>2.40 [1.38, 4.17] | *   |  |
| Yeo et al 2020         42         60         31         60         12.2%           Subtotal (95% Cl)         471         471         100.0%           Total events         390         298   | 1.35 [1.01, 1.82]<br>1.29 [1.07, 1.56]                      | •   |  |
| Heterogeneity: Tau* = 0.05; Chi* = 48.60, df = 7 (P < 0.00001); I* = 86%<br>Test for overall effect: Z = 2.70 (P = 0.007)<br>1.1.2 Delayed CR  |   |   |  |
| Clemmons et al 2018         31         51         15         50         10.8%           Mukhopadhyay et al 2016         34         36         14         36         12.2%           Navari et al 2016         109         163         88         168         18.3% | 2.03 [1.26, 3.27]<br>2.43 [1.60, 3.69]<br>1.28 [1.07, 1.53] | <b>.</b>  |  |
| Osman et al 2018         24         34         10         47         8.6%           Tan et al 2009         44         56         26         46         15.5%           Tienchaiananda et al 2019         10         20         5         19         5.1%           | 3.32 [1.84, 5.99]<br>1.39 [1.04, 1.85]<br>1.90 [0.80, 4.54] | +   |  |
| Vimolchalao et al 2020         22         32         14         32         11.2%           Yeo et al 2020         52         60         44         60         18.3%           Subtotal (95% Cl)         452         458         100.0%                             | 1.57 [0.99, 2.48]<br>1.18 [0.99, 1.42]<br>1.64 [1.31, 2.06] | •   |  |
| $\begin{array}{l} \mbox{Total events} & 326 & 216 \\ \mbox{Heterogeneity: Tau^2 = 0.06; Chi^2 = 24.27, df = 7 (P = 0.001); P = 71\% \\ \mbox{Test for overall effect: } Z = 4.30 (P < 0.0001) \end{array}$   |   |   |  |
| 1.1.3 Overall CR           Clemmons et al 2018         28         51         13         50         11.2%           Mukhopadhyay et al 2016         33         36         13         36         13.4%   | 2.11 [1.24, 3.59]<br>2.54 [1.63, 3.96]                      | ÷   |  |
| Navari et al 2016         103         162         69         170         20.6%           Osman et al 2018         23         34         7         47         7.7%           Tan et al 2009         44         56         26         46         18.2%               | 1.57 [1.26, 1.94]<br>4.54 [2.21, 9.35]<br>1.39 [1.04, 1.85] | ÷   |  |
| Tienchaiananda et al 2019         10         20         4         19         4.9%           Vimolchalao et al 2020         22         32         8         32         8.9%           Yeo et al 2020         35         60         23         60         15.1%      | 2.38 [0.90, 6.30]<br>2.75 [1.44, 5.24]<br>1.52 [1.03, 2.24] |   |  |
| Subtotal (95% Cl)         451         460         100.0%           Total events         298         163           Heterogeneity: Tau <sup>a</sup> = 0.06; Chi <sup>a</sup> = 16.70, df = 7 (P = 0.02); l <sup>a</sup> = 58%  | 1.96 [1.54, 2.49]   | •   |  |
| Test for overall effect $Z\!\equiv\!5.48~(P<0.00001)$  | 0.0   | 1 0.1 1 10 100  |  |
| Test for subaroup differences: Chi <sup>a</sup> = 7.53. df = 2 (P = 0.02). I <sup>a</sup> = 73.4% ${\ensuremath{B}}$   |   | Favours [control] Favours [olanzapine]                  |  |
| D Olanzapine Control<br><u>Study or Subgroup</u> Events Total Events Total Weight<br>1.2.1 Acute CR  | Risk Ratio<br>M-H, Fixed, 95% Cl                            | Risk Ratio<br>M-H, Fixed, 95% Cl                        |  |
| Jacon et al 2019         28         29         22         25         20.2%           Mukhopadhyay et al 2016         14         14         13         14         11.5%           Osman et al 2018         15         16         29         34         15.8%        | 1.10 (0.93, 1.29)<br>1.07 (0.89, 1.30)<br>1.10 (0.91, 1.33) | ŧ   |  |
| Tan et al 2009         63         65         60         62         52.4%           Subtotal (95% Cl)         124         135         100.0%           Total events         120         124   | 1.00 [0.94, 1.07]<br>1.04 [0.98, 1.11]                      | Ŧ   |  |
| Heterogeneity: Chi <sup>2</sup> = 2.45, df = 3 (P = 0.48); $ ^2 = 0\%$<br>Test for overall effect: Z = 1.43 (P = 0.15)   |   |   |  |
| 1.2.2 Delayed CR           Jeon et al 2019         20         29         12         25         16.5%           Mukhopadhyay et al 2016         14         14         7         14         9.6%   | 1.44 [0.89, 2.31]<br>1.93 [1.16, 3.23]                      |   |  |
| Osman et al 2018         11         16         15         34         12.3%           Tan et al 2009         58         65         47         62         61.6%           Subtotal (95% Cl)         124         135         100.0%                                   | 1.56 [0.94, 2.58]<br>1.18 [1.00, 1.39]<br>1.34 [1.15, 1.56] | •   |  |
| $\label{eq:total_total_total} \begin{array}{l} 103 \qquad 81\\ \mbox{Heterogeneity: } Chi^{2} = 4.77, \mbox{ df} = 3 \mbox{ (P} = 0.19);  i^{2} = 37\%\\ \mbox{Test for overall effect: } Z = 3.73 \mbox{ (P} = 0.0002) \end{array}$                               |   |   |  |
| 1.2.3 Overall CR           Jeon et al 2019         20         29         12         25         16.6%           Mukhopadhyay et al 2016         14         14         7         14         9.7%   | 1.44 [0.89, 2.31]<br>1.93 [1.16, 3.23]                      |   |  |
| Osman et al 2018 10 16 14 34 11.6%<br>Tan et al 2009 58 65 47 62 62.1%<br>Subtotal (95% CI) 124 135 100.0%   | 1.52 [0.87, 2.64]<br>1.18 [1.00, 1.39]<br>1.33 [1.14, 1.56] |   |  |
| Total events         102         80           Heterogeneity: Chi <sup>a</sup> = 4.52, df = 3 (P = 0.21); l <sup>a</sup> = 34%         34%           Test for overall effect: Z = 3.62 (P = 0.0003)         36%   |   |   |  |
|  | 0.01  | 0.1 1 10 100<br>Favours [control] Favours [colanzapine] |  |
| Test for subaroup differences: Chi <sup>p</sup> = 15.01. df = 2 (P = 0.0006). I <sup>p</sup> = 86 C  | 7%  |   |  |
| Olanzapine Control<br><u>Study or Subgroup</u> Events Total Events Total Weight M-<br>1.1.1 Acute CR   |   | Risk Ratio<br>M-H, Random, 95% Cl                       |  |
| Hashimoto, H. 2019         336         354         311         351         100.0%           Subtotal (95% Cl)         354         351         100.0%           Total events         336         311  | 1.07 [1.02, 1.12]<br>1.07 [1.02, 1.12]                      | 7   |  |
| Heterogeneity: Not applicable<br>Test for overall effect: Z = 3.02 (P = 0.002)   |   |   |  |
| 1.1.2 Delayed CR           Hashimoto, H. 2019         280         354         231         351         100.0%           Subtotal (95% CI)         354         351         100.0%  | 1.20 [1.10, 1.32]<br>1.20 [1.10, 1.32]                      | -   |  |
| Total events 280 231<br>Heterogeneity: Not applicable<br>Test for overall effect: Z = 3.90 (P < 0.0001)  |   |   |  |
| 1.1.3 Overall CR<br>Hashimoto, H. 2019 276 354 223 351 100.0%  | 1.23 [1.11, 1.35]   |   |  |
| Subtotal (95% CI)         354         351         100.0%           Total events         276         223           Heterogeneity: Not applicable         354         351  | 1.23 [1.11, 1.35]   | •   |  |
| Test for overall effect: Z = 4.15 (P < 0.0001)   | 0.01  | 0.1 1 10 100  |  |
| Test for subaroup differences: Chi <sup>a</sup> = 9.39. df = 2 (P = 0.009). $i^a$ = 78.7   |   | Favours [control] Favours [olanzapine]                  |  |
| D Olanzapine Control<br>Study or Subgroup Events Total Events Total Weight M-H   | Risk Ratio  | Risk Ratio<br>M-H, Random, 95% Cl                       |  |
| 1.2.1 Acute CR<br>Clemons, M. 2020 111 113 102 105 68.4%<br>Mizukami, N. 2014 22 22 19 22 31.6%  | 1.01 [0.97, 1.05]   |   |  |
| Subtotal (95% Cl)         135         127         100.0%           Total events         133         121           Heterogeneily: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 2.46, df = 1 (P = 0.12); I <sup>2</sup> = 59%   | 1.05 [0.92, 1.21]   | ł   |  |
| Test for overall effect: Z = 0.76 (P = 0.45)<br>1.2.2 Delayed CR   |   |   |  |
| Clemons, M. 2020         109         113         100         105         57.4%           Mizukami, N. 2014         22         22         16         22         42.6%           Subtotal (95% Cl)         135         127         100.0%                            | 1.01 [0.96, 1.07]<br>1.36 [1.05, 1.77]<br>1.15 [0.83, 1.60] | <b>•</b>  |  |
| Total events 131 116<br>Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 6.18, df = 1 (P = 0.01); I <sup>2</sup> = 84%<br>Test for overall effect: Z = 0.83 (P = 0.41)   |   |   |  |
| 1.2.3 Overall CR<br>Clemons, M. 2020 108 113 97 105 57.4%  | 1.03 [0.97, 1.11]   | <b>_</b>  |  |
| Mizukami, N. 2014 22 22 15 22 42.6%  | 1.45 [1.09, 1.94]<br>1.19 [0.83, 1.72]                      | *   |  |
| Subtotal (95% CI)         135         127         100.0%           Total events         130         112           Heterogeneity: Tau <sup>a</sup> = 0.06; Chi <sup>a</sup> = 6.02, df = 1 (P = 0.01); I <sup>a</sup> = 83%   |   |   |  |

FIGURE 1 | Complete response (CR). (A) CR of 10mg Olz for HEC. (B) CR of 10mg Olz for MEC. (C) CR of 5mg Olz for MEC. (D) CR of 5mg Olz for HEC/MEC.

|  | A Olanzapine Control Risk Ratio<br><u>Study or Subarcoup Events Total Events Total Weight M-H, Random, 95% Cl</u><br>2.1.1 Acute CC  |
|--|--|
|  | Chemome et al 2019 30 61 22 50 72% 1.28 (0.89, 187)<br>Mukhopadhyar et al 2016 1.38 1.38 0.7% 1.00 (0.7, 15.39)<br>Chemome et al 2018 2016 1.38 1.38 0.47 7.3% 1.28 (0.89, 187)<br>Timenzialamonate et al 2019 0.0 2.51 0.2 2.5% 4.75 (1.15, 18.82)<br>Timenzialamonate et al 2019 0.0 2.5 1.2 2.5% 4.75 (1.15, 18.82)<br>Vinochalamonate et al 2010 0.0 2.5 2.5% 4.75 (1.10, 2.42)<br>Vinochalamonate et al 2020 17 22 8.32 5.2% 2.13 (1.0, 2.42)<br>Vinochalamonate et al 2020 17 22 8.32 5.2% 2.13 (1.0, 2.42)<br>Vinochalamonate et al 2020 17 22 8.32 5.2% 4.13 (1.0, 2.42)<br>Vinochalamonate et al 2020 17 24 1.20 2.5% 4.75 (1.10, 2.42)<br>Vinochalamonate et al 2020 17 24 1.20 2.5% 4.75 (1.10, 2.42)<br>Vinochalamonate et al 2020 17 24 1.20 2.5% 4.75 (1.10, 2.42)<br>Vinochalamonate et al 2020 17 24 1.20 2.5% 4.75 (1.10, 2.42)<br>Vinochalamonate et al 2.2% 4.75 (1.10, 2.42)<br>Vinochalamonate et al 2.2% 4.75 (1.10, 2.42)<br>Vinochalamonate et al 2.2.45 (7 = 0.07) (Vinochalamonate et al 2.2.45 (7 = 0.05)), 7 = 80%   |
|  | 2.1.2 Delayed CC     Celemons et al 2016     7     51     8     50     4.8%     2.08 (0.99, 4.39)       Mothogadhyay et al 2016     0     36     13     38     0.7%     0.04 (0.00, 0.00)       Orman et al 2019     2.8     12     47     52%     3.02 (1.75, 5.05)       Tan et al 2009     39     56     14     46     6.5%     2.29 (1.43, 3.66)       Tenchalanad et al 2019     7     0     3     9.2%     3.22 (0.87, 7.34)       Vimorkhalas et al 2020     13     32     4.5%     3.25 (1.19, 8.50)       Yes et al 2020     13     32     4.5%     3.25 (1.19, 8.50)       Vimorkhalas et al 2020     13     32     6.5%     3.25 (1.19, 8.50)       Yes et al 2016     2.39     5.7%     1.69 (1.20, 3.08)       Subtocal (59% CC)     2.89     3.27%     1.69 (1.20, 3.08)       Total events     0.24 (1.74 = 2.7) (1.47 = 8.6%     5%       Heidrogeneity: Tariat "Counts" = 2.1 (1.47 = 6.6% - 0.001); P = 73%       Test for oreal affect Z = 2.72 (P = 0.001);  |
|  | 2.1.3 Overall CC       Cervinose 41 4076       13       51       6       50       4.0%       2.12 (0.88, 515)         Michogaethyny et al 2016       1       36       50       4.0%       2.12 (0.88, 515)         Jordian et al 2019       25       4.9       4.7       56%       3.84 (0.08, 10, 10, 516)         Tan et al 2009       39       56       1       46       6.4%       2.46 (1.51, 4.03)         Tienchalandate et al 2019       6       0       10       16       5.5%       3.26 (1.10, 8.50)         Vinochalae et al 2020       13       32       4.5%       3.25 (1.10, 8.50)         Vinochalae et al 2020       13       10       16       6.5%       1.34 (1.10, 3.15)         Subtocal (55% C)       2.89       2.80%       2.24 (1.31, 3.81)       Total events         Total events       2.38 (-1)       7.5%       2.32 (1.13, 3.81)       Total events         Total events       2.38 (-1)       7.5%       3.25%       3.25%   |
|  | Total (95% CI)         867         870         100.0%         1.32 (1.43, 2.32)           Total vertes         455         282         100         100         100           Hetrogrenity:Tau*=0.17, Chrk=80.80, df=20 (JP < 0.0001); fr=75%   |
|  | B         Olanzapine         Centrol         Risk Ratio         Risk Ratio           Study or Subarcos         Fvents         Total         Weight         Mul. Fixed, 95% C1         Mul. Fixed, 95% C1           Acute Co         Acute Co         Subarcos         Fvents         Total         Vents         Fvents           Total         vents         15         16         20         34         24.4%         108 (108), 127           Total events         15         16         20         34         24.5%         108 (108), 127           Total events         10         100.0%         1.05 [0.08, 1.13]         Interview         Interview           Fotal events         70.1         9         8         100 (10.0%         1.05 [0.08, 1.13]         Interview           Feat for oracid field C2         1.07 (10.0%         1.05 [0.08, 1.13]         Interview         Interview         Interview  |
|  | 2.2.2 Delayed CC<br>Mukhopadhyay et al 2016 0 14 4 14 6.7% 0.11 [0.01, 1.89]<br>Grama et al 2019 12 16 16 34 18.8% 1.59[ [0.1, 2.51]<br>Tan et al 2009 54 65 38 62 71.4% 1.43[ 11.3, 18.2]<br>Subtotal (59C1) 5 10 100.0% 1.35 [ 1.09, 1.67]<br>Total events 65<br>Total events 65<br>Heterogenetic Ch <sup>a</sup> = 3.74, df = 2 f e = 0.15, f = 4.7%<br>Test for overall effect Z = 2.75 (f = 0.006)  |
|  | 2.2.3 Overall CC<br>Mukhopadayoy et al 2016 0 14 4 14 9.0% 0.11 [0.01, 1.89]<br>Oaman et al 2018 11 16 15 34 19.2% 1.5e [0.34, 2.59]<br>Tant et al 2009 54 65 35 62 7.176 % 1.47 [1.5, 1.89]<br>Total revents 65 5 410 100.0% 1.37 [1.09, 1.70]<br>Total revents 65 5 410 100.0% 1.37 [1.09, 1.70]   |
|  | 0.01 0.1 1 10 100<br>Test for suborous differences: Chi <sup>2</sup> = 8.54. df = 2 (P = 0.01). P= 78.8%.<br>Favours (Control) Favours (Otanzapine)  |
|  | C         Olanzapine         Control         Risk Ratio         Nisk Ratio           Study of Subarcou         Events         Total         Vents         Total  |
|  | 2.1.2 Delayed CC<br>Hashimoto, H. 2019 276 354 223 351 100.0% 1.201(1.1,1.35]<br>Total events 276 223 351 100.0% 1.23 (1.11, 1.35]<br>Hidrogonenity, Not applicable<br>Test for overall effect Z = 4.15 (* 0.0001)   |
|  | 2.1.3 Overall CC<br>Hashmoo, H, 2019 270 354 214 351 100.0% 1.25 [1.13, 1.39]<br>Subtotal (9% 0) 354 351 100.0% 1.25 [1.13, 1.39]<br>Total events 270 214<br>Heterogenetic Most applicable   |
|  | Test for overall effect Z = 4.31 (P = 0.0001)  |
|  | lest for Subdroub americance: Un * = 1 in ab. (If * 2 /u = 2,0,0,1) * = 8,2 + 70<br>D Olanzapine Control Risk Ratio Risk Ratio Risk Ratio Risk Ratio Risk Ratio Control Function Control Risk Ratio Risk |
|  | 22.1 Acute CC     C       Clemons, M, 2020     89     11.3     71     105     93.8%     1.15 [0.98, 1.36]       Mizukami, N, 2014     14     22     5     22     6.4%     2.80 [1.22, 6.44]       Subtoral (6%) C0     135     127     100.0%     1.26 [1.06, 1.49]       Total events     102     76       Heterogeneity, Chi* = 46.3, of 1 = (P = 0.03);     P = 73%       Test for overall effect Z = 2.87 (P = 0.008)  |
|  | 2.2.2.Delayed CC<br>Clemons, M. 2020 88 113 71 105 9.3.6% 1.15 [0.98, 1.38]<br>Mitudam, N. 2014 14 22 5 12 6.4% 2.80 [1.22, 6.44]<br>Subtotal [6% Cu) 13 5 127 100.0% 1.28 [1.66, 1.49]<br>Total events 102 76<br>Heterogenetic, Cu <sup>++</sup> = 4.8, 3f = (1.9 - 0.03); F = 78%<br>Test for overall affect Z = 2.67 (P = 0.08)   |
|  | 2.2.3 Overall CC<br>Clemons, M, 2020 02 113 62 105 92.8% 1.23[1.01,1.49]<br>Mitukami, N. 2014 13 22 5 22 7.2% 2.80[1.12, 8.05]<br>Subtotal (6%) G1 135 127 100.0% 1.33 (1.09, 1.61]<br>Total events<br>Heterogenee(): Cht <sup>2</sup> 3.03, dt = (f ≠ 0.004); t <sup>2</sup> 6.7%<br>Test for overall effect Z = 2.86 (r ≠ 0.004).  |
|  | 0.01 0.1 1 10 100<br>Test for suborouo differences: Chi" = 0.23. df = 2 (P = 0.89), I" = 0%, Favours [control] Favours [clanzapine]  |
| FIGURE 2   Complete control (CC). (A) CC | of 10mg Olz for HEC. (B) CC of 10mg Olz for MEC. (C) CC of 5mg Olz for MEC. (D) CC of 5mg Olz for HEC/MEC.   |

For MEC patients, 5 mg olanzapine was clinically superior to the placebo control group for delay (RD = 0.13) and overall (RD = 0.14) CR. For patients with HEC/MEC, 5 mg olanzapine was clinically superior to the control protocol in delay (RD = 0.13) and overall (RD = 0.16) CR (**Table 3**).

### **Complete** Control

For MEC patients, 5 mg olanzapine has statistical advantages in acute (RR = 1.07, 95% CI = 1.02,1.12), delayed (RR = 1.23, 95% CI = 1.11,1.35), and overall (RR = 1.25, 95% CI = 1.13,1.39) CC (**Figure 2C**). Similarly, for patients with HEC/MEC, 5 mg olanzapine has statistical advantages in acute (RR = 1.26, 95% CI = 1.06,1.49), delayed (RR = 1.26, 95% CI = 1.06,1.49), and overall (RR = 1.33, 95% CI = 1.09,1.61) CC (**Figure 2D**).

For MEC patients, 5 mg olanzapine has clinical advantages for delay (RD = 0.14) and overall (RD = 0.15) CC. For patients with HEC/MEC, 5 mg olanzapine was clinically superior to the control protocol in acute (RD = 0.23), delayed (RD = 0.23), and overall (RD = 0.23) CC (**Table 3**).

### 3.5 Safety of Olanzapine for the Prophylaxis of CINV Somnolence

The sedation of the 10- and 5-mg olanzapine groups was statistically significant than that of the control group. The sedation of the 10-mg olanzapine group was more significant than that of the 5-mg olanzapine group, both statistically (**Figure 3**) and clinically (**Table 3**).

### 3.6 Subgroup Analysis of Different Regions


Taking into account the ethnic differences in different regions, we conducted a subgroup analysis between the Asian and non-Asian countries. For antiemetic effects of olanzapine, there was no significant difference between Asian and non-Asian countries statistically (**Figure 4**).

**TABLE 3** | Absolute risk difference between olanzapine and other regimens for statistically significant differences.

| Endpoint                        | Risk difference<br>(95% confidence<br>interval) | Clinically significant? |  |
|---------------------------------|---|-------------------------|--|
| 10 mg OLZ for HEC-acute CR      | 0.18 [0.07, 0.29]                               | YES                     |  |
| 10 mg OLZ for HEC-delayed CR    | 0.29 [0.17, 0.40]                               | YES                     |  |
| 10 mg OLZ for HEC-overall CR    | 0.34 [0.23, 0.44]                               | YES                     |  |
| 10 mg OLZ for MEC-acute CR      | 0.04 [-0.01, 0.10]                              | NO                      |  |
| 10 mg OLZ for MEC-delayed CR    | 0.21 [0.11, 0.31]                               | YES                     |  |
| 10 mg OLZ for MEC-overall CR    | 0.20 [0.10, 0.31]                               | YES                     |  |
| 5 mg OLZ for MEC-acute CR       | 0.06 [0.02, 0.10]                               | NO                      |  |
| 5 mg OLZ for MEC-delayed CR     | 0.13 [0.07, 0.20]                               | YES                     |  |
| 5 mg OLZ for MEC-overall CR     | 0.14 [0.08, 0.21]                               | YES                     |  |
| 5 mg OLZ for HEC/MEC-acute CR   | 0.05 [-0.07, 0.18]                              | NO                      |  |
| 5 mg OLZ for HEC/MEC-delayed CR | 0.13 [-0.14, 0.40]                              | YES                     |  |
| 5 mg OLZ for HEC/MEC-overall CR | 0.16 [-0.13, 0.45]                              | YES                     |  |
| 10 mg OLZ for HEC-acute CC      | 0.16 [0.04, 0.29]                               | YES                     |  |
| 10 mg OLZ for HEC-delayed CC    | 0.19 [-0.04, 0.41]                              | YES                     |  |
| 10 mg OLZ for HEC-overall CC    | 0.22 [0.01, 0.44]                               | YES                     |  |
| 10 mg OLZ for MEC-acute CC      | 0.04 [-0.02, 0.10]                              | NO                      |  |
| 10 mg OLZ for MEC-delayed CC    | 0.09 [-0.26, 0.43]                              | NO                      |  |
| 10 mg OLZ for MEC-overall CC    | 0.08 [-0.27, 0.43]                              | NO                      |  |
| 5 mg OLZ for MEC-acute CC       | 0.06 [0.02. 0.10]                               | NO                      |  |
| 5 mg OLZ for MEC-delayed CC     | 0.14 [0.08, 0.21]                               | YES                     |  |
| 5 mg OLZ for MEC-overall CC     | 0.15 [0.09, 0.22]                               | YES                     |  |
| 5 mg OLZ for HEC/MEC-acute CC   | 0.23 [-0.07, 0.53]                              | YES                     |  |
| 5 mg OLZ for HEC/MEC-delayed CC | 0.23 [-0.07,0.53]                               | YES                     |  |
| 5 mg OLZ for HEC/MEC-overall CC | 0.22 [0.00, 0.43]                               | YES                     |  |
| 10 mg OLZ-somnolence            | 0.20 [0.03, 0.37]                               | YES                     |  |
| 5 mg OLZ-somnolence             | 0.10 [0.04, 0.17]                               | YES                     |  |
| <b>y</b>                        | - L   |                         |  |

## **4 DISCUSSION**

Twelve studies were included in this study to explore the balance between the efficacy and sedation of olanzapine in the prevention of CINV, to minimize sedation while ensuring the maximum efficacy, and to provide some guidance for improving the quality of life of patients in terms of medication.



Meta-analysis showed that for adult patients receiving HEC, 10 mg olanzapine was more statistically superior (six endpoints) than 5 mg olanzapine (three endpoints), but their clinical advantages were similar. This result suggests that 10 mg olanzapine may be a prior choice for HEC patients, and 5 mg olanzapine may be a clinical choice for patients without obvious risk of CINV (**Tables 4, 5**).

In adult patients receiving MEC, 5 mg olanzapine showed obvious advantage both statistically (six endpoints) and

clinically (four endpoints) compared with 10 mg olanzapine (four endpoints and two endpoints). Moreover, 5 mg olanzapine has statistical advantages in acute CR and CC, which suggests the doctors do not need to rescue the patients after the chemotherapy. Therefore, 5 mg olanzapine may be a prior choice for MEC patients.

Compared with the onset of acute nausea and vomiting, both 10 mg olanzapine and 5 mg olanzapine showed better




FIGURE 4 | Subgroup analysis of different regions. (A) CR of Olz for Asia or non-Asia countries. (B) CR of Olz for Asia or non-Asia countries.

| The dose<br>of<br>olanzapine | The category    |              | CR           |              | CC           |              |         |
|------------------------------|-----------------|--------------|--------------|--------------|--------------|--------------|---------|
|                              | of chemotherapy | Acute        | Delay        | Overall      | Acute        | Delay        | Overall |
| 10 mg                        | HEC<br>MEC      | $\checkmark$ |              |              |              |              |         |
| 5 mg                         | HEC             |              | V            | V            | $\checkmark$ | v<br>√       | v<br>√  |
|                              | MEC             | $\checkmark$ | $\checkmark$ | $\checkmark$ | $\checkmark$ | $\checkmark$ |         |

#### TABLE 4 | Statistical advantages of olanzapine for the prophylaxis of CINV.

**TABLE 5** | Clinical advantages of olanzapine for the prophylaxis of CINV.

| The dose         | The category    | CR    |              |         | cc           |              |              |
|------------------|-----------------|-------|--------------|---------|--------------|--------------|--------------|
| of<br>olanzapine | of chemotherapy | Acute | Delay        | Overall | Acute        | Delay        | Overall      |
| 10 mg            | HEC             |       | $\checkmark$ |         |              |              |              |
|                  | MEC             |       |              |         |              |              |              |
| 5 mg             | HEC             |       |              |         | $\checkmark$ | $\checkmark$ |              |
|                  | MEC             |       |              |         |              | $\checkmark$ | $\checkmark$ |

preventive effects in the delayed period and overall. The better effect of olanzapine in the delayed phase and overall may be due to the lower incidence of vomiting and nausea in the acute phase (42).

It is worth paying attention the side effects of olanzapine, which was originally used as an antipsychotic. In the study by Jeon (33), 10 mg olanzapine showed only a few cases of mild sedation in the description of sedation, suggesting that sedation was not significant. However, in the study by Navari (31), a large number of statistical data indicated that the drowsiness effect of 10 mg olanzapine was significantly different from that of placebo. Similar reports have been reported for 5 mg olanzapine, although less than for 10 mg.

Therefore, we also analyzed the sedative effect of two doses of olanzapine in this meta-analysis, and the results showed that there was indeed a sedative effect of olanzapine, but the effect intensity in the 5-mg group was significantly lower than that in the 10-mg group and was not as significant as that in the placebo group. Combined with the above 5-mg olanzapine group in patients receiving MEC, the combination of 5 mg olanzapine may be a better option for the prevention of CINV, but we need to wait for the performance of 5 mg olanzapine in patients receiving HEC and more information on the sedative effect of 5 mg olanzapine.

A recent Phase II clinical study (15) reported that 5 mg olanzapine had a better antiemetic effect than 10 mg olanzapine, and its adverse reactions (e.g., sedation) were lower than those of the 10-mg olanzapine group. As the efficacy of olanzapine in emesis control significantly exceeded that of the placebo, and taking the possible increased risk of adverse drug reactions (ADRs) with the dose increase into consideration, olanzapine at a dose of 5 mg per day should be recommended for the prophylaxis of CINV. If patients fail to achieve CR, the dose can be increased to 10 mg in the next chemotherapy cycle.

At present, the occurrence of CINV still cannot be completely controlled. Multiple studies have shown that the overall response rates of acute and delayed CINV in HEC patients treated with the triple regimen are 75% to 80% and 57% to 70%, respectively, and the incidence of nausea is more than 50%. This still falls short of the expected goal of 100% mitigation of CINV (43–45). The mechanism of action of olanzapine is that it binds to the dopamine receptor, cholinergic receptor, and histamine H1 receptor and plays an antagonistic role. It reduces the stimulation of the chemoreceptor triggering area (CTZ) and thus reduces the occurrence of vomiting. At present, the effect of olanzapine has also been affirmed in the Guidelines for the Prevention and Treatment of Nausea and Vomiting Related to CSCO Anti-tumor Therapy. However, OLZ is currently mainly used in patients who are resistant to the combination of drugs, which may be due to the sedative effect of olanzapine. Our study showed that a low dose of olanzapine may have significant effects in the prevention of CINV and few adverse reactions, which may be helpful for the clinical use of olanzapine after the chemotherapy.

Limitations: (1) Although the drug regimens for the prevention of CINV in the control group included in the experiment all adopted the regimens in the guidelines of various countries, there were differences in the regimens of each trial. There was some bias in remission rate. (2) The cancer type, malignancy degree, and purpose of chemotherapy of cancer patients are different, and some may affect the occurrence of CINV. (3) There are great differences in the descriptions of sedation in the literature, and there is no unified standard to judge the intensity of sedation, which may lead to errors in the results of sedation. (4) The quality of the literature included in this study is different, and the difference in the experimental results may lead to deviation in the results of this meta-analysis. (5) The sample size of some studies is small and may not be representative.

## DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**. Further inquiries can be directed to the corresponding author.

## **AUTHOR CONTRIBUTIONS**

D-YW: data curation, methodology, visualization, writing original draft, and writing—review and editing. YC: data curation, methodology, visualization, writing—original draft, and writing—review and editing. YZ: conceptualization, methodology, project administration, writing—original draft, and writing—review and editing. Y-QS: conceptualization, methodology, project administration, writing—original draft, and writing—review and editing. All authors contributed to the article and approved the submitted version.

## FUNDING

This study was supported by the Innovation and Entrepreneurship Training Scheme for university students

## REFERENCES

- Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. New Engl J Med (2016) 374(14):1356–67. doi: 10.1056/ NEJMra1515442
- Okada Y, Oba K, Furukawa N, Kosaka Y, Okita K, Yuki S, et al. One-Day Versus Three-Day Dexamethasone in Combination With Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. Oncologist (2019) 24(12):1593–600. doi: 10.1634/theoncologist.2019-0133
- Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for Classifying the Acute Emetogenicity of Cancer Chemotherapy. *J Clin Oncol* (1997) 15(1):103–9. doi: 10.1200/JCO.1997.15.1.103
- Morrow GR, Hickok JT, Burish TG, Rosenthal SN. Frequency and Clinical Implications of Delayed Nausea and Delayed Emesis. *Am J Clin Oncol* (1996) 19(2):199–203. doi: 10.1097/00000421-199604000-00023
- Jordan K, Gralla R, Jahn F, Molassiotis A. International Antiemetic Guidelines on Chemotherapy Induced Nausea and Vomiting (Cinv): Content and Implementation in Daily Routine Practice. *Eur J Pharmacol* (2014) 722:197–202. doi: 10.1016/j.ejphar.2013.09.073
- Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol (2011) 29(31):4189–98. doi: 10.1200/ JCO.2010.34.4614
- Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety. *Oncologist* (2015) 20(4):450–8. doi: 10.1634/theoncologist.2014-0229
- Pirl WF, Roth AJ. Remission of Chemotherapy-Induced Emesis With Concurrent Olanzapine Treatment: A Case Report. *Psychooncology* (2000) 9(1):84–7. doi: 10.1002/(SICI)1099-1611(200001/02)9:1<84::AID-PON440> 3.0.CO;2-T
- Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R. Olanzapine as an Antiemetic in Refractory Nausea and Vomiting in Advanced Cancer. *J Pain Symptom Manage* (2003) 25(6):578–82. doi: 10.1016/S0885-3924(03) 00143-X
- Navari RM, Einhorn LH, Passik SD, Loehrer PJSr, Johnson C, Mayer ML, et al. A Phase II Trial of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Hoosier Oncology Group Study. Support Care Cancer (2005) 13(7):529–34. doi: 10.1007/s00520-004-0755-6
- 11. Navari RM, Einhorn LH, Loehrer PJ, Passik SDSr, Vinson J, McClean J, et al. A Phase II Trial of Olanzapine, Dexamethasone, and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Hoosier Oncology Group Study. *Support Care Cancer* (2007) 15(11):1285. doi: 10.1007/s00520-007-0248-5
- 12. Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S, et al. Efficacy and Safety of Olanzapine Combined With Aprepitant, Palonosetron, and Dexamethasone for Preventing Nausea and Vomiting Induced by Cisplatin-

Program (No. C202110611401) from West China School/ Hospital of Stomatology Sichuan University.

### ACKNOWLEDGMENTS

The authors acknowledge support from the National Clinical Research Center for Oral Diseases.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021. 705866/full#supplementary-material

Based Chemotherapy in Gynecological Cancer: KCOG-G1301 Phase II Trial. Support Care Cancer (2016) 24(2):675–82. doi: 10.1007/s00520-015-2829-z

- Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, et al. NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw (2017) 15(7):883–93. doi: 10.6004/jnccn.2017.0117
- Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol (2017) 35(28):3240–61. doi: 10.1200/JCO.2017.74.4789
- Hashimoto H, Yanai T, Nagashima K, Tsuda NO, Horinouchi H, Takiguchi T, et al. A Double-Blind Randomized Phase II Study of 10 Versus 5 Mg Olanzapine for Emesis Induced by Highly Emetogenic Chemotherapy With Cisplatin. J Clin Oncol (2016) 34(15\_suppl):10111. doi: 10.1200/JCO.2016. 34.15\_suppl.10111
- 16. Hashimoto H, Abe M, Nakao M, Mizutani H, Sakata Y, Fujita Y, et al. A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Evaluating Olanzapine 5 Mg Combined With Standard Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Cisplatin-Based Chemotherapy: J-FORCE Study. J Clin Oncol (2019) 37(15\_suppl):11503. doi: 10.1200/JCO.2019.37.15\_suppl.11503
- Hashimoto H, Abe M, Nakao M, Mizutani H, Sakata Y, Fujita Y, et al. A Phase III Trial Evaluating Olanzapine 5mg for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Cisplatin: J-FORCE Study. Ann Oncol (2019) 30:v721–2. doi: 10.1093/annonc/mdz265.010
- Abe M, Yanai T, Daga H, Takei D, Iwamoto Y, Minato K, et al. A Randomized, Double-Blind, Placebocontrolled Phase III Trial Evaluating Olanzapine 5 Mg and Standard Antiemetic Therapy for Preventing CINV Caused by Cisplatin-Based Chemotherapy: J-Force Study. Supportive Care Cancer (2019) 27(1):S37. doi: 10.1007/s00520-019-04813-1
- Abe M, Yanai T, Nakashima K, Hirashima Y, Murakami H, Hamauchi S, et al. A Randomized, Double-Blind, Placebo-Controlled Phase Iii Study Evaluating Olanzapine 5mg Combined With Standard Antiemetic Therapy for the Prevention of Cinv in Patients Receiving Cisplatin-Based Chemotherapy. Supportive Care Cancer (2017) 25(2):S63. doi: 10.1007/s00520-017-3704-x
- Hashimoto H, Yanai T, Nagashima K, Tsuda NO, Horinouchi H, Takiguchi T, et al. A Double-Blind Randomized Phase II Study of 10 versus 5 Mg Olanzapine for Emesis Induced by Highly Emetogenic Chemotherapy with Cisplatin. J Clin Oncol (2016) 34(15\_suppl):10111. doi: 10.1200/ JCO.2016.34.15\_suppl.10111
- Ctri. Old Drug in New Dose: Olanzapine in Chemotherapy Induced Nausea & Vomiting, Does Dose Matters? (2020). Available at: http://www.who.int/ trialsearch/Trial2.aspx?TrialID=CTRI/2020/02/023589.
- 22. Ctri. A Study on Comparison of Addition of Olanzapine 5 Mg Versus Olanzapine 10 Mg as Anti-Emetic to Standard Anti-Emetic Regime for Doxorubicin and Cyclophosphamide in Breast Cancer (2020). Available at: http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/01/023076.
- 23. Jprn, U. A Double-Blind Randomized Phase II Study of Olanzapine 10mg Versus 5mg for Highly Emetogenic Chemotherapy-Induced Nausea and

Vomiting (2014). Available at: http://www.who.int/trialsearch/Trial2.aspx? TrialID=JPRN-UMIN000014214.

- 24. Jprn, U. A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Evaluating Olanzapine 5mg Combined With Standard Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Cisplatin-Based Highly Emetogenic Chemotherapy: J-SUPPORT 1604 (2016). Available at: http://www.who.int/trialsearch/Trial2.aspx?TrialID= JPRN-UMIN000024676.
- 25. Jprn, U. A Placebo-Controlled, Double-Blind, Randomized Phase III Study to Validate the Efficacy of Standard Antiemetic Therapy Plus Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Chemotherapy Including Carboplatin (2019). Available at: http://www.who. int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000037749.
- 26. Nakashima K, Murakami H, Yokoyama K, Omori S, Wakuda K, Ono A, et al. A Phase II Study of Palonosetron, Aprepitant, Dexamethasone and Olanzapine for the Prevention of Cisplatin-Based Chemotherapy-Induced Nausea and Vomiting in Patients With Thoracic Malignancy. *Jpn J Clin Oncol* (2017) 47(9):840–3. doi: 10.1093/jjco/hyx084
- 27. Suehiro M, Kojima Y, Takahashi M, Ito Y, Keira T, Ikegawa K, et al. Antiemetic Efficacy of Adding Olanzapine 5 Mg to Aprepitant, Palonosetron and Dexamethasone-Sparing After Day Two for Cancer Patients Receiving Anthracycline and Cyclophosphamide. *Cancer Manage Res* (2021) 13:1617–24. doi: 10.2147/CMAR.S280995
- Clemons M, Dranitsaris G, Sienkiewicz M, Sehdev S, Ng T, Robinson A, et al. A Randomized Trial of Individualized Versus Standard of Care Antiemetic Therapy for Breast Cancer Patients at High Risk for Chemotherapy-Induced Nausea and Vomiting. *Breast (Edinburgh Scotland)* (2020) 54:278–85. doi: 10.1016/j.breast.2020.11.002
- Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, et al. Olanzapine 5 Mg Plus Standard Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting (J-FORCE): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. *Lancet Oncol* (2020) 21(2):242–9. doi: 10.1016/S1470-2045(19)30678-3
- Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study. J Pain Symptom Manage (2014) 47(3):542–50. doi: 10.1016/j.jpainsymman.2013.05.003
- Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med (2016) 375(2):134–42. doi: 10.1056/NEJMoa1515725
- 32. Yeo W, Lau TK, Li L, Lai KT, Pang E, Cheung M, et al. A Randomized Study of Olanzapine-Containing Versus Standard Antiemetic Regimens for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients. *Breast* (2020) 50:30–8. doi: 10.1016/j.breast.2020.01.005
- 33. Jeon SY, Han HS, Bae WK, Park MR, Shim H, Lee SC, et al. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study. Cancer Res Treat (2019) 51(1):90–7. doi: 10.4143/crt.2017.577
- 34. Mukhopadhyay S, Kwatra G, Alice KP, Badyal D. Role of Olanzapine in Chemotherapy-Induced Nausea and Vomiting on Platinum-Based Chemotherapy Patients: A Randomized Controlled Study. *Supportive Care Cancer* (2016) 25(1):145–54. doi: 10.1007/s00520-016-3386-9
- Osman AAM, Elhassan MMA, AbdElrahim BHA, Ahmed FHA, Yousif JBH, Ahmed MAM, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan. J Glob Oncol (2018) 4:1–9. doi: 10.1200/JGO.17.00216
- 36. Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, et al. Clinical Research of Olanzapine for Prevention of Chemotherapy-Induced Nausea and Vomiting. *J Exp Clin Cancer Res* (2009) 28(1):131. doi: 10.1186/1756-9966-28-131
- 37. Tienchaiananda P, Nipondhkit W, Maneenil K, Sa-Nguansai S, Payapwattanawong S, Laohavinij S, et al. A Randomized, Double-Blind,

Placebo-Controlled Study Evaluating the Efficacy of Combination Olanzapine, Ondansetron and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Doxorubicin Plus Cyclophosphamide. *Ann Palliat Med* (2019) 8(4):372–80. doi: 10.21037/apm.2019.08.04

- 38. Vimolchalao V, Sakdejayont S, Wongchanapai P, Sukprakun S, Angspatt P, Thawinwisan W, et al. The Efficacy and Safety of the Addition of Olanzapine to Ondansetron and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy. *Int J Clin Oncol* (2020) 25(2):396–402. doi: 10.1007/s10147-019-01570-3
- 39. Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial. *Biol Blood Marrow Transplant* (2018) 24 (10):2065–71. doi: 10.1016/j.bbmt.2018.06.005
- 40. Abe M, Kasamatsu Y, Kado N, Kuji S, Tanaka A, Takahashi N, et al. Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy. *BioMed Res Int* (2015) 2015:956785. doi: 10.1155/2015/956785
- 41. Kawazoe H, Uozumi R, Murakami A, Yamashita M, Kobayashi-Taguchi K, Kusakabe E, et al. Olanzapine Plus Aprepitant, Palonosetron, and Dexamethasone for Nausea and Vomiting in Patients With Breast Cancer Receiving Anthracycline: A Retrospective Study. *Sci Rep* (2018) 8(1):16232. doi: 10.1038/s41598-018-34618-x
- Navari RM. Prevention of Emesis From Multiple-Day and High-Dose Chemotherapy Regimens. J Natl Compr Canc Netw (2007) 5(1):51–9. doi: 10.6004/jnccn.2007.0007
- 43. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie MG, Eldridge K, Hipple A, et al. Addition of the Neurokinin 1 Receptor Antagonist Aprepitant to Standard Antiemetic Therapy Improves Control of Chemotherapy-Induced Nausea and Vomiting. Results From a Randomized, Double-Blind, Placebo-Controlled Trial in Latin America. *Cancer* (2003) 97(12):3090–8. doi: 10.1002/cncr.11433
- 44. Yang LQ, Sun XC, Qin SK, Cheng Y, Shi JH, Chen ZD, et al. Efficacy and Safety of Fosaprepitant in the Prevention of Nausea and Vomiting Following Highly Emetogenic Chemotherapy in Chinese People: A Randomized, Double-Blind, Phase III Study. *Eur J Cancer Care (Engl)* (2017) 26(6): e12668. doi: 10.1111/ecc.12668
- 45. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, et al. Palonosetron Plus Dexamethasone Versus Granisetron Plus Dexamethasone for Prevention of Nausea and Vomiting During Chemotherapy: A Double-Blind, Double-Dummy, Randomised, Comparative Phase III Trial. *Lancet* Oncol (2009) 10(2):115–24. doi: 10.1016/S1470-2045(08)70313-9

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Chen, Zhang and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.